CD3-Binding Antibodies Optimizing Affinity and Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Designing therapeutic antibodies that target CD3 with high specificity and affinity while balancing immunological effects is challenging due to the complexity of T-cell activation and its involvement in various diseases such as cancer and autoimmune disorders.
Innovation Solution
Development of antibodies or antibody fragments with amino acid sequences at least 90% identical to specific sequences (SEQ ID NOs: 25-32) that bind to CD3 with a dissociation constant (KD) of less than 75 nM, including monoclonal, polyclonal, and humanized forms, generated through methods like phage display and library design to optimize binding affinity and immunological tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies are designed to target CD3 with high specificity and affinity, then binding affinity is improved, but immunological side effects worsen
Solution Approach 1:
The patent applies local quality by modifying specific regions of the antibody molecule (humanizing CDRs while retaining non-human framework regions) to achieve high CD3 binding affinity while reducing immunogenicity. This selective modification of local antibody regions allows optimization of binding properties without compromising overall safety
Solution Approach 2:
The patent employs parameter changes by systematically varying the sequence identity percentages (90%, 95%, 97%, 99% identical to SEQ ID NOs: 25-32) and dissociation constants (KD < 75 nM, < 50 nM, < 25 nM, < 10 nM) to optimize the balance between binding affinity and reduced immunogenicity, demonstrating how parameter adjustment resolves the contradiction
2Reliability
If antibodies are designed with high specificity to CD3, then binding specificity is improved, but design complexity worsens
Solution Approach 1:
The patent applies segmentation by dividing the antibody into functional regions (heavy chain variable domain with CDRH1, CDRH2, CDRH3 and light chain variable domain with CDRL1, CDRL2, CDRL3) that can be independently optimized. This modular approach allows systematic design of specific CD3-binding antibodies while managing complexity through structured organization
Solution Approach 2:
The patent employs universality by designing antibodies with standardized framework regions that can accommodate multiple CDR sequence variants (SEQ ID NOs: 25-32), creating a universal platform for generating high-specificity CD3-binding antibodies through systematic variation of key binding regions rather than redesigning entire antibody molecules
Data Source
AI summary
Provided herein are methods and compositions relating to CD3 libraries having nucleic acids encoding for a scaffold comprising a CD3 domain. CD3 libraries described herein encode for immunoglobulins such as antibodies.